These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 27429464)

  • 1. Presumed masitinib-induced nephrotic syndrome and azotemia in a dog.
    Devine L; Polzin DJ
    Can Vet J; 2016 Jul; 57(7):752-6. PubMed ID: 27429464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Masitinib is safe and effective for the treatment of canine mast cell tumors.
    Hahn KA; Ogilvie G; Rusk T; Devauchelle P; Leblanc A; Legendre A; Powers B; Leventhal PS; Kinet JP; Palmerini F; Dubreuil P; Moussy A; Hermine O
    J Vet Intern Med; 2008; 22(6):1301-9. PubMed ID: 18823406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "Masitinib" is safe and effective for the treatment of canine mast cell tumors.
    Gentilini F
    J Vet Intern Med; 2010; 24(1):6; author reply 7. PubMed ID: 20391634
    [No Abstract]   [Full Text] [Related]  

  • 4. Toceranib phosphate-associated nephrotic syndrome in a dog: a case report.
    Remerowski SM; Herrera CL; Donnelly LL
    BMC Vet Res; 2021 Apr; 17(1):146. PubMed ID: 33827545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microalbuminuria is not associated with cisplatin-induced azotemia in dogs.
    Autio K; Rassnick KM; Goldstein RE; Erb HN
    J Vet Intern Med; 2007; 21(6):1198-202. PubMed ID: 18196726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective review of treatment and response of high-risk mast cell tumours in dogs.
    Miller RL; Van Lelyveld S; Warland J; Dobson JM; Foale RD
    Vet Comp Oncol; 2016 Dec; 14(4):361-370. PubMed ID: 25223579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Masitinib mesylate for metastatic and non-resectable canine cutaneous mast cell tumours.
    Smrkovski OA; Essick L; Rohrbach BW; Legendre AM
    Vet Comp Oncol; 2015 Sep; 13(3):314-21. PubMed ID: 23845124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical response of masitinib mesylate in the treatment of canine macroscopic mast cell tumours.
    Grant J; North S; Lanore D
    J Small Anim Pract; 2016 Jun; 57(6):283-90. PubMed ID: 27136424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Masitinib-associated minimal change disease with acute tubular necrosis resulting in acute kidney injury in a dog.
    Brown MR; Cianciolo RE; Nabity MB; Brown CA; Clubb FJ; Lees GE
    J Vet Intern Med; 2013; 27(6):1622-6. PubMed ID: 24020652
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of signalment, clinicopathologic findings, histologic diagnosis, and prognosis in dogs with glomerular disease with or without nephrotic syndrome.
    Klosterman ES; Moore GE; de Brito Galvao JF; DiBartola SP; Groman RP; Whittemore JC; Vaden SL; Harris TL; Byron JK; Dowling SR; Grant DC; Grauer GF; Pressler BM
    J Vet Intern Med; 2011; 25(2):206-14. PubMed ID: 21281353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine hemangiosarcoma cell lines.
    Lyles SE; Milner RJ; Kow K; Salute ME
    Vet Comp Oncol; 2012 Sep; 10(3):223-35. PubMed ID: 22594682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors.
    Hahn KA; Legendre AM; Shaw NG; Phillips B; Ogilvie GK; Prescott DM; Atwater SW; Carreras JK; Lana SE; Ladue T; Rusk A; Kinet JP; Dubreuil P; Moussy A; Hermine O
    Am J Vet Res; 2010 Nov; 71(11):1354-61. PubMed ID: 21034327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nephrotic syndrome associated with administration of sulfadimethoxine/ormetoprim in a dobermann.
    Vasilopulos RJ; Mackin A; Lavergne SN; Trepanier LA
    J Small Anim Pract; 2005 May; 46(5):232-6. PubMed ID: 15909446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomized, double-blind, placebo-controlled phase 3 trial.
    Cadot P; Hensel P; Bensignor E; Hadjaje C; Marignac G; Beco L; Fontaine J; Jamet JF; Georgescu G; Campbell K; Cannon A; Osborn SC; Messinger L; Gogny-Goubert M; Dubreuil P; Moussy A; Hermine O
    Vet Dermatol; 2011 Dec; 22(6):554-64. PubMed ID: 21668810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcitriol (1,25-dihydroxycholecalciferol) enhances mast cell tumour chemotherapy and receptor tyrosine kinase inhibitor activity in vitro and has single-agent activity against spontaneously occurring canine mast cell tumours.
    Malone EK; Rassnick KM; Wakshlag JJ; Russell DS; Al-Sarraf R; Ruslander DM; Johnson CS; Trump DL
    Vet Comp Oncol; 2010 Sep; 8(3):209-20. PubMed ID: 20691028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of masitinib mesylate in healthy cats.
    Daly M; Sheppard S; Cohen N; Nabity M; Moussy A; Hermine O; Wilson H
    J Vet Intern Med; 2011; 25(2):297-302. PubMed ID: 21314730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute azotemia as a predictor of mortality in dogs and cats.
    Harison E; Langston C; Palma D; Lamb K
    J Vet Intern Med; 2012; 26(5):1093-8. PubMed ID: 22882549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nephrotic syndrome associated with tyrosine kinase inhibitors for pediatric malignancy: case series and review of the literature.
    Ruebner RL; Copelovitch L; Evageliou NF; Denburg MR; Belasco JB; Kaplan BS
    Pediatr Nephrol; 2014 May; 29(5):863-9. PubMed ID: 24310825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and progression of proteinuria in dogs treated with masitinib for neoplasia: 28 cases (2010-2019).
    Kuijlaars M; Helm J; McBrearty A
    J Small Anim Pract; 2021 Aug; 62(8):646-654. PubMed ID: 33634470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Masitinib (AB1010), from canine tumor model to human clinical development: where we are?
    Marech I; Patruno R; Zizzo N; Gadaleta C; Introna M; Zito AF; Gadaleta CD; Ranieri G
    Crit Rev Oncol Hematol; 2014 Jul; 91(1):98-111. PubMed ID: 24405856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.